ART Advanced Research Technologies to Present Molecular Imaging Applications at AACR Meeting in Denver

  ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be exhibiting at the Annual Meeting of the American Association for Cancer Research (AACR), April 19-22, in Denver, Colorado. ART will showcase its preclinical product offering, including current research in oncology and related fields using the Optix® optical imaging device, as well as the Fenestra® line of contrast agents for microCT imaging, at its booth (#757) located in the Colorado Convention Center.

The Annual Meeting of the American Association for Cancer Research (AACR) is the world's largest and most comprehensive gathering of professionals in the cancer field, encompassing basic, translational, and clinical research. This prestigious annual event highlights the latest developments in cancer research and is attended by over 17,000 delegates from universities, research institutions and the pharmaceutical industry.

About the Optix® system

Based on time-domain technology, which allows measurement of the light's time of arrival, the Optix® in vivo optical molecular imaging device is the most sensitive optical imager commercially available on the preclinical market, allowing for detection of lower concentrations of signals deeper inside the body. Unique to the Optix system is the ability to recover fluorescence lifetime, which can be used to separate and quantify probe distributions depending on their respective biochemical environment. Also part of the Optix product offering is a CT fusion software package allowing researchers to export the scan obtained using Optix in DICOM format, and fuse it with microCT for a full 3D anatomical reference.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART is commercializing some of these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2008, available on SEDAR (www.sedar.com).

Contacts: ART ADVANCED RESEARCH TECHNOLOGIES INC. Jacques Bedard Chief Financial Officer [e-mail] www.art.ca ART ADVANCED RESEARCH TECHNOLOGIES INC. Dino DiCamillo Vice President, Global Sales and Marketing, Preclinical Research 514-832-0777 [e-mail]